Clinical trials: gemcitabine hydrochloride
Fallopian Tube Cancer, Ovarian Cancer
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00217555
- Testing
- gemcitabine hydrochloride, topotecan hydrochloride
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Carcinoma, Non-Small-Cell Lung
Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy
This study evaluates the effect of the serum level of Superoxide Dismutase (SOD), Malondialdehyde (MDA), pro-inflammatory factors, stress hormones and Glutathione peroxidase (GSH-PX)in tumor patients with the treatment of…
- Trial name
- LCKY2015-21(x) (NCT02844114)
- Testing
- Ganoderma lucidum spore, Chemotherapy
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gao Yajie
Leiomyosarcoma, Adult
Targeting ATR in Soft-tissue Sarcomas
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of berzosertib in association with gemcitabine
- Trial name
- TARSARC (NCT04807816)
- Testing
- Association of berzosertib with gemcitabine, Gemcitabine
- Where
- 5 sites in France
- Volunteers
- 58 people
- Sponsor
- Institut Bergonié
Squamous Non-small-cell Lung Cancer
Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)
The purpose of this study is to investigate the efficacy and the safety of paclitaxel liposome and cisplatin compared with gemcitabine and cisplatin as first-line therapy in advanced squamous non-small-cell lung cancer .
- Trial name
- LIPUSU (NCT02996214)
- Testing
- Paclitaxel Liposome, Gemcitabine, Cisplatin
- Volunteers
- 536 people
- Sponsor
- Nanjing Luye Sike Pharmaceutical Co., Ltd.
Extranodal NK-T-Cell Lymphoma, Early-stage
A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102)
The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent Anti-PD-1 antibody in early-stage…
- Conditions
- Extranodal NK-T-Cell Lymphoma, Early-stage, High-Risk Cancer
- Trial name
- CLCG-2102 (NCT05254899)
- Testing
- Anti-PD-1 monoclonal antibody, Pegaspargase, Gemcitabine
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cholangiocarcinoma Non-resectable
Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer
The goal of this single-arm, Phase II interventional clinical trial is to test the safety and effectiveness of a combination treatment using the Cadonilimab with Gemcitabine and Cisplatin in patients with unresectable, locally…
- Trial name
- NCT05978609
- Testing
- Candonilimab, Cisplatin, Gemcitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- West China Hospital
Cancer of Pancreas, Chemotherapy Effect
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment.
- Conditions
- Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer
- Trial name
- NCT04769414
- Testing
- Gemcitabine fluorouracil
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Menoufia University
Neoplasms
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with…
- Trial name
- NCT03918278
- Testing
- MK-0482, pembrolizumab, Paclitaxel
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 222 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumors
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
This study will investigate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) activity of adavosertib, both as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in participants with…
- Trial name
- NCT00648648
- Testing
- adavosertib, gemcitabine, cisplatin
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC
Preoperative chemotherapy is considered to play a role in early stage non small cell lung cancer (NSCLC) .The use of preoperative Cisplatin/Gemcitabine chemotherapy has proven feasible and without excessive morbidity or mortality…
- Trial name
- NCT00191126
- Testing
- gemcitabine, Cisplatin, surgery
- Where
- 37 sites in Belgium, Bosnia and Herzegovina and 13 more
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma
Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma
The study evaluates impact of high dose radiation on overall survival in patients with unresectable nonmetastatic cholangiocarcinoma.
- Trial name
- NCT02773485
- Testing
- High Dose Radiation, Systemic chemotherapy
- Where
- India
- Volunteers
- 155 people
- Sponsor
- Tata Memorial Hospital
Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
This pilot phase I trial studies the side effects of gemcitabine hydrochloride, nab-paclitaxel, metformin hydrochloride, and a standardized dietary supplement in treating patients with pancreatic cancer that cannot be removed by…
- Conditions
- Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02336087
- Testing
- Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma
Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
The primary aim of this study is to determine the presence of gemcitabine in childhood diffuse midline gliomas (DMG) (previously classified as diffuse intrinsic pontine glioma [DIPG]) after systemic treatment with the drug.
- Conditions
- Glial Tumor of Brain, Diffuse Intrinsic Pontine Glioma, Glioma
- Trial name
- NCT04051047
- Testing
- Gemcitabine, Tumor biopsy and blood draw
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Adenocarcinoma
Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer
This is an open-label, non-randomized Phase II study to evaluate immunochemotherapy in patients with R0 OR R1-resected pancreatic cancer.
- Trial name
- ATIP (NCT00395252)
- Testing
- Cetuximab (Erbitux®) and Gemcitabine
- Where
- 8 sites in Germany
- Volunteers
- 76 people
- Sponsor
- Carmen Schade-Brittinger
Breast Cancer
Study Comparing Concomitant Docetaxel + Gemcitabine to Sequential Therapy of Docetaxel Followed by Gemcitabine
The purpose of this study is to compare the Time To Disease Progression (TTDP) between those patients with unresectable, locally recurrent or metastatic breast cancer who are treated with concomitant Docetaxel plus Gemcitabine to…
- Trial name
- NCT00294385
- Testing
- Docetaxel, Gemcitabine, Docetaxel
- Where
- 18 sites in Austria, Bulgaria and 5 more
- Volunteers
- 430 people
- Sponsor
- Central European Cooperative Oncology Group
Non-Small-Cell Lung Cancer
Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
This is a prospective pilot phase II trial, in patients with wet stage IIIb and IV NSCLC using chemotherapy regimens which will be defined according to the pharmacogenomic profile (tumoral expression of ERCC1, BRCA1 and RRM1) of…
- Trial name
- NCT00705549
- Testing
- Gemcitabine, Cisplatin, Docetaxel
- Where
- 9 sites in Greece
- Volunteers
- 88 people
- Sponsor
- Hellenic Oncology Research Group
Pancreatic Cancer
Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer
Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT01218880
- Testing
- M2ES 7.5mg, M2ES 15mg, M2ES 30mg
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Metastatic Pancreatic Cancer
Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients
The majority patients diagnosed with pancreatic cancer have metastatic disease at the time of diagnosis. The prognosis is extremely poor with a 5-year survival rate of less than 5%.
- Trial name
- PACT-ACT-v6 (NCT02707159)
- Testing
- Nab paclitaxel / gemcitabine
- Where
- Norway
- Volunteers
- 70 people
- Sponsor
- Helse Stavanger HF
Breast Cancer
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408408
- Testing
- bevacizumab, capecitabine, cyclophosphamide
- Where
- 442 sites in United States, Canada and 1 more
- Volunteers
- 1,206 people
- Sponsor
- NSABP Foundation Inc
Biliary Tract Tumors
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
- Trial name
- Spring (NCT06892925)
- Testing
- QL1706
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.